Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Dyadic International, Inc.

DYAI

Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.31 – $0.326
Volume 34,967
Market cap $13M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$12.83M
Price / earnings
—
Price / book
-4.98×
Price / sales
4.16×
EV / sales
3.87×
EV / EBITDA
-1.63×

Profitability

Earnings per share
-$0.17
Return on assets
-88.27%
Return on equity
271.67%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-1.18×
Current ratio
1.69×
Quick ratio
1.69×
Cash ratio
0.84×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.04M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for DYAI, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$449.1K$961.14K$1.11M$565.53K$1.16M$966.63K$393.57K$817.38K
Cost of revenue$375.12K$984.17K$791.84K$384.61K$1.02M$613.59K$297.66K$352.82K
Gross profit$73.99K-$23.03K$319.12K$180.92K$140.61K$353.04K$95.91K$464.56K
Selling, general and administrative$1.45M$1.69M$1.76M$1.25M$1.48M$1.44M$1.6M$1.44M
Research and development$429.95K$332.62K$476.07K$458.44K$571.87K$629.38K$494.98K$545.66K
Total operating expenses$1.88M$2.02M$2.23M$1.71M$2.05M$2.07M$2.09M$1.99M
Operating income-$1.81M-$2.05M-$1.91M-$1.52M-$1.91M-$1.71M-$2M-$1.52M
Interest expense-$109.53K-$109.39K-$109.18K-$114.39K-$114.11K-$113.83K-$113.56K-$126.23K
Income before taxes-$1.36M-$2.12M-$1.95M-$1.57M-$1.98M-$1.79M-$2.03M-$1.55M
Income taxes$0$0$0$0$0$0$0$0
Net income-$1.36M-$2.12M-$1.95M-$1.57M-$1.98M-$1.79M-$2.03M-$1.55M
Net income attributable to common shareholders-$1.36M-$2.12M-$1.95M-$1.57M-$1.98M-$1.79M-$2.03M-$1.55M
EBITDA-$1.81M-$2.05M-$1.92M-$1.53M-$1.92M-$1.72M-$2.01M-$1.54M
Basic earnings per share-$0.04-$0.06-$0.05-$0.04-$0.06-$0.06-$0.07-$0.05
Diluted earnings per share-$0.04-$0.06-$0.05-$0.04-$0.06-$0.06-$0.07-$0.05

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program

Dyadic International announced expansion of its bio-industrial pipeline with a new proprietary industrial enzyme program for advanced cellulose processing, building on the success of EN3ZYME™. The program leverages the company's Dapibus™ platform to develop tailored enzyme solutions for pulp biorefining, microcrystalline cellulose, and nanocellulose production. Dyadic plans multiple commercialization pathways including direct sales, partnerships, contract manufacturing, and licensing.

GlobeNewswire Inc.

Skyline Corporate Communications Group, LLC Announces Dyadic Applied BioSolutions to Deliver a Live Presentation at the Skyline Signature Series™ on Wednesday, May 27 at 12:00 PM ET

Dyadic International, Inc. (Nasdaq: DYAI), a biotechnology company specializing in precision-engineered proteins and enzymes, will deliver a live interactive presentation at the Skyline Signature Series on May 27, 2026 at 12:00 PM ET. The event will allow investors to ask questions in real time and requires pre-registration.

GlobeNewswire Inc.

Industrial Enzymes Global Industry Forecast Report and Company Analysis 2024-2030 Featuring BASF, Advanced Enzyme Technologies, Novozymes, DuPont Danisco, DSM, Kerry, Dyadic, Associated British Foods

The global industrial enzymes market is expected to grow from $7.03 billion in 2024 to $12.05 billion by 2033, driven by the increasing demand for sustainable manufacturing and the growing use of enzymes in various industries. The report analyzes the market by types, applications, sources, and countries, and provides insights on key players in the industry.

GlobeNewswire Inc.

Dyadic Expands Global Presence with Participation in Key Industry Events

Dyadic International, a biotechnology company, announced its participation in several industry events worldwide, including the Developing Countries Vaccine Manufacturers Network (DCVMN) Int'l Annual Meeting 2024, the World Vaccine Congress Europe 2024, and BIO-Europe. The company aims to showcase its proprietary C1 and Dapibus™ technology platforms for producing vaccines, therapeutics, and non-pharmaceutical products.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.